The content on this site is intended for healthcare professionals only
Dr Lamar speaks with ecancertv at ASH 2016 about phase I dose escalation of CPI-613, a metabolic inhibitor, in combination with bendamustine.
She summarises the incidence and outlook of refractory T cell non-Hodgkin lymphoma (NHL), and the escalation of a small patient subgroup from 2000mg/m2, limited by toxicity.
The overall response rate was 80%, and Dr Lamar describes these initial results as signs of an important crack in the armour of T cell lymphoma.
CPI-613 was discussed further by Dr Tim Pardee here.
ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients
Advancements in minimal residual disease detection in myeloma
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Revolutionising myeloma treatment through immune profiling
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
Encouraging results using mismatched unrelated donors in stem cell transplantation
Multiple myeloma in a resource constrained setting
